Search clinical trials for: Sonelokimab (M1095)

Total 16 results

Bond Avillion 2 Development LP
Avillion LLP

Completed

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

Psoriasis

United States, Germany, Bulgaria, Canada, Czechia, Hungary, Poland
MoonLake Immunotherapeutics AG

Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Spain, Bulgaria, Poland, Czechia, Estonia, Germany, Hungary
MoonLake Immunotherapeutics AG

Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Germany, United States, Bulgaria, Canada, Ireland, Netherlands, Poland
MoonLake Immunotherapeutics AG

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Merck KGaA, Darmstadt, Germany

Completed

Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

Psoriasis

Germany
Ajax Therapeutics, Inc.

Not yet recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | PMF | Post-Essential Thrombocythemia Myelofibrosis | PPV-MF | PET-MF

United States
MoonLake Immunotherapeutics AG

Recruiting

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Bionorica SE

Completed

Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome

Premenstrual Syndrome | Cyclic Mastodynia

Czech Republic
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

Prostate Cancer

United States
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate | Prostatic Neoplasm | Progressive mCRPC

United States, Canada
Bionorica SE

Terminated

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

Mastodynia | Premenstrual Syndrome

Germany
Bionorica SE
FGK Clinical Research GmbH

Recruiting

Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Primary Dysmenorrhea

Poland, Hungary, Germany, Czechia, Austria, Sweden
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States

Search clinical trials for: Sonelokimab (M1095)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations